How does sunitinib cause hypothyroidism?
作者信息
Hershman Jerome M, Liwanpo Llanyee
出版信息
Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.
PMID:20187779
Abstract
摘要
相似文献
1
How does sunitinib cause hypothyroidism?
Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.
2
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.
3
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者中的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. doi: 10.1093/jnci/djm008. Epub 2007 Jun 12.
4
5
Sunitinib and hypothyroidism.舒尼替尼与甲状腺功能减退症。
N Engl J Med. 2007 Apr 12;356(15):1580; author reply 1580-1. doi: 10.1056/NEJMc070327.
6
Sunitinib induces hypothyroidism with a markedly reduced vascularity.舒尼替尼可导致甲状腺功能减退症，并显著降低血管生成。
Thyroid. 2010 Mar;20(3):323-6. doi: 10.1089/thy.2009.0414.
7
Fatigue with sunitinib-induced hypothyroidism.舒尼替尼诱导的甲状腺功能减退伴疲劳。
Lancet Oncol. 2007 Feb;8(2):101. doi: 10.1016/s1470-2045(07)70016-5.
8
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.舒尼替尼治疗的转移性肾细胞癌患者中的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.
9
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?服用苹果酸舒尼替尼的转移性肾细胞癌患者中的高脂血症和甲状腺功能减退。相关还是不相关的不良事件？
Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009. Epub 2014 Sep 22.
10
[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].[舒尼替尼治疗晚期肾细胞癌患者的甲状腺功能障碍：一个多因素问题]
Endocrinol Nutr. 2010 Dec;57(10):486-91. doi: 10.1016/j.endonu.2010.06.002. Epub 2010 Aug 10.
引用本文的文献
1
The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.伊马替尼治疗慢性髓性白血病相关肝毒性和甲状腺毒性的发生率：系统评价。
Int J Clin Pharm. 2024 Apr;46(2):368-381. doi: 10.1007/s11096-023-01671-0. Epub 2023 Dec 26.
2
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors.甲状腺自身免疫和甲状腺功能减退与接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的深度分子缓解相关。
J Endocrinol Invest. 2022 Feb;45(2):291-300. doi: 10.1007/s40618-021-01613-5. Epub 2021 Jul 20.
3
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.舒尼替尼相关大细胞性贫血在转移性肾细胞癌中的临床意义
Cancer Med. 2016 Dec;5(12):3386-3393. doi: 10.1002/cam4.919. Epub 2016 Oct 19.
4
VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.血管内皮生长因子靶向的癌症治疗药物——在内分泌器官中的矛盾效应。
Nat Rev Endocrinol. 2014 Sep;10(9):530-9. doi: 10.1038/nrendo.2014.114. Epub 2014 Jul 22.
Zotero 插件